Alumis Inc. (ALMS) compared with its closest peers (CGEM, VERA, TRDA, KYMR, CUE). Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Cullinan Therapeutics, Vera Therapeutics, Entrada Therapeutics, Kymera Therapeutics, Cue Biopharma, Relay Therapeutics, Geron, Biofrontera, Enveric Biosciences and Precigen share Alumis's sub-industry, pharmaceutical makers.
| Company | Market Cap | P/E |
|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | $1.32B | — |
| Vera Therapeutics, Inc. (VERA) | $2.52B | — |
| Entrada Therapeutics, Inc. (TRDA) | $264.17M | — |
| Kymera Therapeutics, Inc. (KYMR) | $9.56B | — |
| Cue Biopharma, Inc. (CUE) | $208.63M | — |
| Relay Therapeutics, Inc. (RLAY) | $4.13B | — |
| Geron Corporation (GERN) | $864.13M | — |
| Biofrontera Inc. (BFRI) | $23.02M | — |
| Enveric Biosciences, Inc. (ENVB) | $6.36M | — |
| Precigen, Inc. (PGEN) | $2.45B | — |
| Sector P/E (Healthcare) | 19.4 |
| Industry P/E (Pharmaceutical Products) | 15.1 |
ALMS overview · ALMS earnings · ALMS financials · ALMS KPIs · ALMS documents · ALMS ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.